Posted innews Pediatrics
Maternal Nipocalimab Therapy for Severe HDFN: Evidence of Neonatal Safety and Immunological Recovery
The UNITY study demonstrates that antenatal nipocalimab treatment for severe HDFN effectively reduces fetal risk while resulting in only transient neonatal hypogammaglobulinemia. Findings confirm low fetal drug exposure and robust long-term immune recovery, including normal vaccine responses by 96 weeks.